Travere Therapeutics (TVTX) News Today $21.41 +0.26 (+1.23%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$20.75 -0.66 (-3.06%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Freestone Grove Partners LP Takes Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Freestone Grove Partners LP bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 25,521 shares of the company's stock, valued at approximately $445,000May 6 at 4:56 AM | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of "Moderate Buy" from AnalystsTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fifteen research firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have gMay 6 at 2:43 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Posts Earnings Results, Beats Expectations By $0.08 EPSTravere Therapeutics (NASDAQ:TVTX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The firm had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. During the same period in the prior year, the company posted ($1.76) EPS. The company's revenue was up 83.3% on a year-over-year basis.May 5 at 11:07 AM | marketbeat.comAnalysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter ReportMay 4 at 1:46 PM | finance.yahoo.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $23.00 at Stifel NicolausStifel Nicolaus raised their price objective on shares of Travere Therapeutics from $22.00 to $23.00 and gave the company a "hold" rating in a research report on Friday.May 4 at 10:46 AM | marketbeat.comAquatic Capital Management LLC Invests $557,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX)Aquatic Capital Management LLC acquired a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 31,967 shares of the company's stock, valued at approximately $557May 4 at 4:37 AM | marketbeat.comWedbush Reiterates Outperform Rating for Travere Therapeutics (NASDAQ:TVTX)May 4 at 3:27 AM | americanbankingnews.comStifel Nicolaus Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock PriceMay 4 at 3:27 AM | americanbankingnews.comRA Capital Management L.P. Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)RA Capital Management L.P. acquired a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,150,000 shares of the company's sMay 3 at 7:49 AM | marketbeat.comTower Research Capital LLC TRC Grows Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Tower Research Capital LLC TRC grew its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 211.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,367 shares of the company'sMay 3 at 4:12 AM | marketbeat.comCANADA LIFE ASSURANCE Co Acquires 16,416 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)CANADA LIFE ASSURANCE Co raised its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 237.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,318 shares of the company'sMay 3 at 4:01 AM | marketbeat.comTravere Therapeutics’ Earnings Call: Growth Amid ChallengesMay 2, 2025 | tipranks.comTravere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comTravere Therapeutics, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 1, 2025 | seekingalpha.comTravere Therapeutics Reports First Quarter 2025 Financial ResultsMay 1, 2025 | businesswire.comPDT Partners LLC Cuts Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)PDT Partners LLC cut its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 6.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 247,109 shares of the company's stock after selling 17,164 shares during the period. PDT Partners LLC owned apMay 1, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Sells 83,935 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Emerald Mutual Fund Advisers Trust lowered its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,101,774 shares of the company's stock after selling 83,935 shareMay 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $6.56 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Adage Capital Partners GP L.L.C. trimmed its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 376,800 shares of the cMay 1, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Up 6% - What's Next?Travere Therapeutics (NASDAQ:TVTX) Shares Up 6% - Still a Buy?April 30, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Virtus ETF Advisers LLCVirtus ETF Advisers LLC reduced its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 57.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,523 shares of the company's stock after selling 25,967 shares during the quarter. Virtus ETF AdApril 30, 2025 | marketbeat.comTravere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA NephropathyApril 29, 2025 | finance.yahoo.comCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA NephropathyApril 29, 2025 | prnewswire.comTravere Therapeutics (TVTX) to Release Quarterly Earnings on ThursdayTravere Therapeutics (NASDAQ:TVTX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-travere-therapeutics-inc-stock/)April 28, 2025 | marketbeat.comSyon Capital LLC Buys Shares of 15,435 Travere Therapeutics, Inc. (NASDAQ:TVTX)Syon Capital LLC purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,435 shares of the company's stock, valued at approximaApril 28, 2025 | marketbeat.comBarclays PLC Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Barclays PLC increased its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 135.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 396,570 shares of the company's stock after pApril 27, 2025 | marketbeat.comTravere Therapeutics to Report First Quarter 2025 Financial ResultsApril 24, 2025 | finance.yahoo.comSilverarc Capital Management LLC Takes $4.83 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Silverarc Capital Management LLC acquired a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 277,365 shares of the company's stock, valued at approximately $4,832,April 24, 2025 | marketbeat.comEversept Partners LP Has $8.54 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Eversept Partners LP reduced its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 43.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 490,296 shares of the company's stock after selling 379,61April 24, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Up 4.6% - Here's What HappenedTravere Therapeutics (NASDAQ:TVTX) Trading Up 4.6% - Still a Buy?April 23, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Boosted by Rock Springs Capital Management LPRock Springs Capital Management LP increased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 6.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 4,973,649 shares of the company's stock after purchasing an additional 289,173 shares duriApril 23, 2025 | marketbeat.comJump Financial LLC Cuts Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)Jump Financial LLC cut its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 72.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,842 shares of the compApril 22, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Invesco Ltd.Invesco Ltd. raised its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 135.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 858,942 shares of the company's stock after acquiring an additional 493,736April 22, 2025 | marketbeat.comWhat is Wedbush's Estimate for TVTX Q1 Earnings?Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Wedbush issued their Q1 2026 EPS estimates for shares of Travere Therapeutics in a report released on Wednesday, April 16th. Wedbush analyst L. Chico expects that the company will post earnings of ($0.02) per share for the quarter. The consApril 20, 2025 | marketbeat.comGeode Capital Management LLC Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Geode Capital Management LLC grew its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 6.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,842,301 shares of the company's stock after purchasing an additioApril 19, 2025 | marketbeat.comFranklin Resources Inc. Acquires New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Franklin Resources Inc. bought a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 36,238 shares of the company's stock, valued at approximately $631,000. AApril 19, 2025 | marketbeat.comWalleye Capital LLC Sells 61,223 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Walleye Capital LLC reduced its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 12.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 427,230 shares of the company's stock afApril 18, 2025 | marketbeat.comGuggenheim Reiterates "Buy" Rating for Travere Therapeutics (NASDAQ:TVTX)Guggenheim reissued a "buy" rating and set a $47.00 price target on shares of Travere Therapeutics in a research report on Monday.April 16, 2025 | marketbeat.comWellington Management Group LLP Makes New $583,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)Wellington Management Group LLP acquired a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 33,493 shares of the company's stock, valued at apprApril 16, 2025 | marketbeat.com111,158 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Acquired by F M Investments LLCF M Investments LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 111,158 shares of the company's stock, valueApril 14, 2025 | marketbeat.comNorges Bank Takes $1.24 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Norges Bank bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 71,000 shares of the company's stock, valued at approximately $1,237,000. NorgeApril 14, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 534,500 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Renaissance Technologies LLC boosted its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 28.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,409,514 shares of the company's stock after purchasing an additional 534,April 13, 2025 | marketbeat.comFederated Hermes Inc. Acquires 44,500 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Federated Hermes Inc. lifted its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 668,315 shares of the company's stock after purchasing an additional 44,500 shares duriApril 12, 2025 | marketbeat.comScotiabank Remains a Buy on Travere Therapeutics (TVTX)April 11, 2025 | markets.businessinsider.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Time to Sell?Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down - What's Next?April 11, 2025 | marketbeat.comVanguard Group Inc. Sells 159,985 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Vanguard Group Inc. lowered its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 2.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,742,165 shares of the company's stock after selling 159April 10, 2025 | marketbeat.comTravere Therapeutics (TVTX) Receives a Buy from Wells FargoApril 10, 2025 | markets.businessinsider.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by AnalystsTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fourteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and thirteenApril 10, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Trexquant Investment LPTrexquant Investment LP reduced its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 21.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,217 shares of the company's stoApril 7, 2025 | marketbeat.comSchroder Investment Management Group Sells 260,199 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Schroder Investment Management Group trimmed its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 38.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 417,253 shares of the company's stock after selling 260,199 shares during theApril 6, 2025 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Travere Therapeutics (NASDAQ:TVTX)Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a research report on Thursday.April 5, 2025 | marketbeat.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼0.880.72▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼237▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BridgeBio Pharma News Today TG Therapeutics News Today Legend Biotech News Today Sarepta Therapeutics News Today Telix Pharmaceuticals Limited American Depositary Shares News Today ADMA Biologics News Today Blueprint Medicines News Today Verona Pharma News Today Nuvalent News Today Axsome Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy tvtx Stock Free tvtx Stock Alerts